Xenetic Biosciences, Inc. announced that it has entered into a security purchase agreement for the issuance of 850,000 shares at a price of $0.5751 per common share for gross proceeds of $488,835 on October 12, 2022. The transaction will include participation from CLS Therapeutics, LLC. The company will issue securities pursuant to exemption provided under Regulation D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.55 USD | -10.25% | -9.55% | +2.90% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.90% | 6.09M | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- XBIO Stock
- News Xenetic Biosciences, Inc.
- Xenetic Biosciences, Inc. announced that it expects to receive $0.488835 million in funding from CLS Therapeutics, LLC